Skip to main content

Table 3 Multivariate logistic regression of the 5-year disease free status in relation to the poor-prognosis score and other clinical variables

From: Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts

 

All events (n = 159) (number of events = 38)

 

Odds ratio (95% confidence interval)

P value

Poor-prognosis score

4.19 (1.49–11.77)

0.007

Age (per 10 years)

1.11 (0.79–1.54)

0.55

Stage

   Stage 2 versus 1

1.28 (0.4–4.08)

0.68

   Stage 3 versus 1

1.11 (0.42–2.95)

0.83

Elston grade

   Grade 2 versus 1

3.32 (0.63–17.56)

0.16

   Grade 3 versus 1

2.81 (0.5–15.74)

0.24

Estrogen-receptor-positive

2.94 (0.76–11.28)

0.12

Progesterone-receptor-positive

0.35 (0.12–0.99)

0.05